← All trials
NCT03791814
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2019
- Primary completion
- Jun 30, 2019
- Completion date
- Jan 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 71
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yeshiva UniversityLead sponsor
- MerckCollaborator
- Yeshiva UniversityStudy director
- Yeshiva UniversityOverall official - principal investigator
- Yeshiva UniversityReponsible party - principal investigator
- Davita Clinical ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.